请使用支持JavaScript的浏览器!
主营:化学试剂,CCK-8试剂盒,细胞检测,自噬研究,化学标记,生化试剂等
℡ 4000-520-616
℡ 4000-520-616
Dojindo/Biotin Labeling Kit-NH2/1/LK03
产品编号:LK03
市  场 价:¥3760.00
场      地:美国(厂家直采)
产品分类: 蛋白类>多肽>多肽合成>
联系QQ:1570468124
电话号码:4000-520-616
邮      箱: info@ebiomall.com
美  元  价:$188.00
品      牌: Dojindo
公司分类:
Dojindo/Biotin Labeling Kit-NH2/1/LK03
商品介绍
DescriptionReferencesDataQ & AManual(LK03)Manual(LK55)S.D.S(LK03)S.D.S(LK55)

Product Description:Biotin Labeling Kit-NH2 is mainly used for the preparation of biotin-labeled IgG for enzyme immunoassay (EIA). NH2-reactive biotin, a component of this kit, has succinimidyl groups (NHS) that react with amino groups on proteins or other molecules (Fig. 1). This kit contains all the reagents necessary for the labeling. The labeling process is very simple. Just add the NH2- reactive Biotin to IgG solution and incubate at 37oC for 10 minutes. An average of 5 to 8 biotin molecules conjugate to each IgG molecule. The number of biotin molecules per protein can be determined by HABA assay. Excess biotin molecules can be removed by a filtration tube.

Fig. 1 IgG labeling reaction with NH2-reactive biotin

Precaution:♦ The molecular weight of the protein to be labeled with this kit should be greater than 50,000.♦ IgG or biotin-conjugated IgG is always on the membrane of the filtration tube during the labeling process.♦ If the IgG solution contains other proteins with molecular weights larger than 10,000, such as BSA or gelatin, purify the IgG solution before labeling biotin with this kit. IgG solution can be purified by IgG Purification Kits (not included in this kit).♦ If the IgG solution contains small insoluble materials, centrifuge the solution and use the supernatant for the labeling.

Easily Switch Fluorescence wavelength on your primary antibody

1. Y. Kubota, Y. Oike, S. Satoh, Y. Tabata, Y. Niikura, T. Morisada, M. Akao, T. Urano, Y. Ito, T. Miyamoto, N. Nagai, G. Y. Koh, S. Watanabe and T. Suda, “Cooperative Interaction of Angiopoietin-like Proteins 1 and 2 in Zebrafish Vascular Development”, Proc. Natl. Acad. Sci. USA, 2005, 102, 13502.2. T. Yamabuki, A. Takano, S. Hayama, N. Ishikawa, T. Kato, M. Miyamoto, T. Ito, H. Ito, Y. Miyagi, H. Nakayama, M. Fujita, M. Hosokawa, E. Tsuchiya, N. Kohno, S. Kondo, Y. Nakamura, and Y. Daigo, “Dikkopf-1 as a Novel Serologic and Prognostic Biomarker for Lung and Esophageal Carcinomas”, Cancer Res., 2007, 67, 2517.3. H. Kohara, Y. Omatsu, T. Suhiyama, M. Noda, N. Fujii and T. Nagasawa, “Development of Plasmacytoid Dendritic Cells in Bone Marrow Stromal Cell niches Requires CXCL12-CXCR4 Chemokine Signaling”, Blood, 2007, 110, 4153.4. N. Ishikawa, A. Takano, W. Yasui, K. Inai, H. Nishimura, H. Ito, Y. Miyagi, H. Nakayama, M. Fujita, M. Hosokawa, E. Tsuchiya, N. Kohno, Y. Nakamura and Y. Daigo, “Cancer-testis Antigen Lymphocyte Antigen 6 Complex Locus K is a Serologic Biomarker and a Therapeutic Target for Lung and Esophageal Carcinomas”, Cancer Res., 2007, 67, 11601.5. A. Fukuda, T. Goto, K.N. Kuroishi, K.K. Gunjigake, S. Kataoka, S. Kobayashi and K. Yamaguchi, “Hemokinin-1 competitively inhibits substance P-induced stimulation of osteoclast formation and function”, Neuropeptides., 2013, 47, (4), 251.6. A. Ogawa , M. Sakatsume, X. Wang, Y. Sakamaki, Y. Tsubata, B. Alchi, T. Kuroda, H. Kawachi, I. Narita, F. Shimizu and F. Gejyo, “SM22alpha: the novel phenotype marker of injured glomerular epithelial cells in anti-glomerular basement membrane nephritis”, Nephron Exp. Nephrol.., 2007, 106, (3), e77.7. D. Men, T.T. Zhang, L.W. Hou, J. Zhou, Z.P. Zhang, Y.Y. Shi, J.L. Zhang, Z.Q. Cui, J.Y. Deng, D.B. Wang and X.E. Zhang, “Self-Assembly of Ferritin Nanoparticles into an Enzyme Nanocomposite with Tunable Size for Ultrasensitive Immunoassay”, ACS Nano., 2015, 9, (11), 10852.8. D. Sugahara, Y. Kobayashi, Y. Akimoto, H. Kawakami, “Mouse intestinal niche cells express a distinct α1,2-fucosylated glycan recognized by a lectin from Burkholderia cenocepacia”, Glycobiology., 2017, 27, (3), 246.9. H. Sasaki-Iwaoka, M. Ohori, A. Imasato, K. Taguchi, K. Minoura, T. Saito, K. Kushima, E. Imamura, S. Kubo, S. Furukawa and T. Morokata, “Generation and characterization of a potent fully human monoclonal antibody against the interleukin-23 receptor”, Eur. J. Pharmacol.., 2018, 828, 89.10. K. Kaneshiro, M. Watanabe, K. Terasawa, H. Uchimura, Y. Fukuyama, S. Iwamoto, T.A. Sato, K. Shimizu, G. Tsujimoto and K. Tanaka, “Rapid quantitative profiling of N-glycan by the glycan-labeling method using 3-aminoquinoline/α-cyano-4-hydroxycinnamic acid”, Anal. Chem.., 2012, 84, (16), 7146.11. K.S. Tan, K. Kulkeaw, Y. Nakanishi, D. Sugiyama, “Expression of cytokine and extracellular matrix mRNAs in fetal hepatic stellate cells”, Genes Cells., 2017, 22, (9), 836.12. M. Tahara, S. Ohno, K. Sakai, Y. Ito, H. Fukuhara, K. Komase, M.A. Brindley, P.A. Rota, R.K. Plemper, K. Maenaka and M. Takeda, “The receptor-binding site of the measles virus hemagglutinin protein itself constitutes a conserved neutralizing epitope”, J. Virol.., 2013, 87, (6), 3583.13. M. Takahashi, Y. Ishida, D. Iwaki, K. Kanno, T. Suzuki, Y. Endo, Y. Homma and T. Fujita, “Essential role of Mannose-binding lectin-associated serine protease-1 in activation of the complement factor D”, J. Exp. Med.., 2010, 207, (1), 29.14. N. Hosen, Y. Matsunaga, K. Hasegawa, H. Matsuno, Y. Nakamura, M. Makita, K. Watanabe, M. Yoshida, K. Satoh, S. Morimoto, F. Fujiki, H. Nakajima, J. Nakata, S. Nishida, A. Tsuboi, Y. Oka, M. Manabe, H. Ichihara, Y. Aoyama, A. Mugitani , T. Nakao, M. Hino, R. Uchibori, K. Ozawa, Y. Baba, S. Terakura, N. Wada, E. Morii, J. Nishimura, K. Takeda, Y. Oji, H. Sugiyama, J. Takagi and A. Kumanogoh, “The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy”, Nat. Med.., 2017, 23, (12), 1436.15. R. Nishino, A. Takano, H. Oshita, N. Ishikawa, H. Akiyama, H. Ito, H. Nakayama, Y. Miyagi, E. Tsuchiya, N. Kohno, Y. Nakamura and Y. Daigo, “Identification of Epstein-Barr virus–induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer”, Clin. Cancer Res.., 2011, 17, (19), 6272.16. T. Hiono, A. Matsuda, T. Wagatsuma, M. Okamatsu, Y. Sakoda and A. Kuno, “Lectin microarray analyses reveal host cell-specific glycan profiles of the hemagglutinins of influenza A viruses”, Virology., 2019, 527, 132.17. T. Oshima, S. Sato, J. Kato, Y. Ito, T. Watanabe, I. Tsuji, A. Hori, T. Kurokawa and T. Kokubo, “Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers”, Mol. Cancer., 2013, 12, (60), .18. T. Yoshida, N. Shiraki, H. Baba, M. Goto, S. Fujiwara, K. Kume and S. Kume, “Expression patterns of epiplakin1 in pancreas, pancreatic cancer and regenerating pancreas”, Genes Cells., 2008, 13, (7), 667.19. X. Piao, T. Ozawa, H. Hamana, K. Shitaoka, A. Jin, H. Kishi and A. Muraguchi, “TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo”, Oncoimmunology., 2016, 5, (5), e1131380.20. Y. Shimazaki, Y. Kohno, “Successive analysis of antigen trapping and enzymatic digestion on membrane-immobilized avidin”, Anal. Biochem.., 2012, 422, (1), 55.

Determination of Biotin/ Protein RatioThe average number of biotin molecules per IgG molecule should be in the range of 5 and 8. If you need to determine the precise number of biotin molecules per Protein molecule use HABA assay. The following is a HABA assay protocol.

Reagent solution:200 μM HABA (4-hydroxyazobenzene-2-carboxylic acid) solution prepared with PBS, pH 7.4 …………………… 1 ml0.5 mg avidin/ml solution prepared with PBS, pH 7.4 ………………………………………………………………….. 1 mldiluted sample solution (55 μl biotinylated protein solution + 110 μl PBS, pH 7.4)25 μM biotin prepared with a mixed solution (2 volumes of PBS, pH 7.4 + 1 volume of WS buffer)……………… 200 μlPrepare solutions of various concentrations (12.5 μM, 6.25 μM, 3.13 μM, 1.56 μM) with serial dilution …………. 200 μl/ea

Fig. 2 Typical Calibration Curve of HABA Assay

1. Mix HABA solution and avidin solution in a plastic tube.2. Add 100 μl of the HABA-avidin solution to 15 wells for multiple assays (n=3).3. Add 50 μl biotin solution (12.5 μM, 6.25 μM, 3.13 μM, and 1.56 μM) to 3 wells each and 50 μl of diluted sample solution to the rest of the 3 wells.4. Read the O.D. at 405 nm with a reference at 492 nm and prepare a calibration curve using the O.D. of various concentrations of biotin solution. Read the O.D. at 280 nm to determine the protein concentration. (e.g. molar absorptivity of IgG at 280 nm: 216,000).5. Determine the concentration of biotin in the sample solution and calculate the number of biotin molecules per protein.

Can I use this kit for other proteins?

Yes, if the molecular weight is greater than 50,000.

Do I have to use a Filtration tube prior to labeling the protein?

If the protein solution does not contain small molecules with amino groups and the concentration of the protein is 10 mg per ml or about 70 μM, there is no need to use the Filtration tube. Just mix 10 μl of the sample solution with 90 μl of Reaction buffer and add the mixture to a vial of NH2-reactive Biotin. After the reaction, transfer all of the reaction mixture to a Filtration tube, and then follow the protocol starting at step 6.

Do I have to use WS buffer to store the biotin-labeled protein?

You don’t have to use WS buffer. You can choose any kind of buffer according to your experiment.

My sample contains small insoluble material. What should I do?

Spin the sample and use the supernatant for the labeling.

How long is the biotin-labeled protein stable?

If you store the biotin-labeled protein at 0-5ºC, it is stable for 2 months. For longer storage, add 100% volume of glycerol, aliquot, and store at -20ºC (if the protein can be frozen). However, please note that stability depends on the protein itself.

What is the minimum amount of IgG that can be labeled by this kit?

The minimum amount is 10 μg IgG; simply follow the protocol. The labeling ratio remains the same for 10 μg to 100 μg of IgG.

Related Categories Labeling Chemistry

品牌介绍

Dojindo Molecular Technologies,Inc.是美国领先的生命科学研究专用试剂盒和化学品分销商。我们通过提供优质的支持和创新产品,不断扩大客户的满意度,以扩大生命科学研究和开发领域。

我们的公司文化反映出“ Jin”(仁)字符背后的含义,即尊重和关爱他人。当我们公司执行上述任务时,“ Jin”精神始终处于我们思想的最前沿。  


我们如何开始

1996年

作为日本Dojindo实验室的子公司,Dojindo Molecular Technologies,Inc.在马里兰州盖瑟斯堡开业,这是新产品开发的主要设施。开发了诸如DNA损伤定量试剂盒SOD检测试剂盒WST标记试剂盒系列之类的产品,为全球客户提供现成的检测试剂盒。


2000

Dojindo Molecular Technologies,Inc.成为了另一个销售地点,将Dojindo产品带到了北美地区的研究专业人员手中。


2008年

我们搬迁至马里兰州罗克维尔,仅专注于北美的销售和营销活动。我们目前的位置非常接近美国国立卫生研究院(NIH),美国国家癌症研究所(NCI),FDA,约翰·霍普金斯大学的研究人员。


我们不仅向周边地区,而且向我们在美国,加拿大和南美的客户提供日本优质的客户支持和创新产品。

关于同人堂实验室

Dojindo Laboratories由螯合化学领域的著名研究人员上野敬平教授创立。同人堂实验室是1951年第一家将EDTA(乙二胺四乙酸)商业化的日本公司。自那以后,同人堂实验室一直在生产用于支持科学研究进展的试剂。Dojindo实验室的任务是开发用于生命科学研究的创新工具。Dojindo实验室致力于通过科学发现和开发新药物为改善生活质量做出贡献。


自营商城图标
厂家直采
全球直采 正品优价
正品保障图标
正品保障
厂家直发 有线跟踪
解放采购图标
正规清关
CIF100%正规报关,提供发票
及时交付图标
及时交付
限时必达 不达必赔